logo
I've changed my mind on ethanol blending. It's a win India can't afford to slow down

I've changed my mind on ethanol blending. It's a win India can't afford to slow down

The Print3 days ago
I will admit that my views on ethanol blending have evolved over the past three years. While I still believe certain issues need to be addressed—such as pricing and availability—overall, ethanol blending and even Compressed Biogas (CBG) are essential for India's energy security, especially since we still import over 85 percent of our crude oil and just under 60 percent of our natural gas requirements.
However, many social media users have raised concerns about ethanol blending, including reduced fuel economy and potential engine damage. In a post on X, the Ministry of Petroleum and Natural Gas shared a 2022 column of mine on the subject for context.
Today is World Biofuels Day, and over the past week there has been a lot of discussion on social media about biofuels, particularly ethanol. This renewed interest follows Petroleum Minister Hardeep Singh Puri's announcement that India has achieved its ethanol blending target of 20 percent, known as E20 petrol, five years ahead of schedule.
Anti-ethanol arguments 'rubbish'
A couple of days ago, I shared a stage with Puri and interacted with multiple stakeholders in the ethanol ecosystem, including automakers, distillers, and think-tank experts, at an event marking World Biofuels Day. One long-standing criticism of ethanol is that it comes from water-intensive crops such as sugarcane. Puri, who once served as India's ambassador to Brazil—the pioneer in ethanol blending—pointed out that this is not a problem for Brazil because it has a vast land area and over 22 percent of the world's freshwater resources.
'But the fact is,' Puri told me, 'that as ethanol production has grown in India, most ethanol now comes not from sugarcane juice but from by-products of sugarcane processing such as B-heavy and C-heavy molasses. In addition, we use broken, damaged, and surplus foodgrain.' The minister added that second-generation ethanol production from products like bamboo is already taking place in Assam, and new start-ups are exploring ways to convert seaweed into ethanol.
'So, the arguments around food security and water wastage are utterly rubbish. Also, we were producing surplus foodgrain and using Indian taxpayer money to subsidise exports of products like sugar. That is not happening now. A bulk of the savings from reduced crude oil imports is now being transferred to Indian farmers, who have gone from being annadatas to urjadatas.'
Car damage, fuel efficiency?
What about concerns over vehicle damage and reduced fuel efficiency? Most carmakers are clear that all cars sold in India, including imported luxury and performance models, are tuned to accept E20 fuel. The loss in fuel efficiency, despite ethanol's lower energy density compared to petrol, is around 1–2 percent, as backed by a 2021 NITI Aayog expert committee report. However, older vehicles—especially those sold before ethanol blending gained momentum under the Narendra Modi government—may see a 5–7 percent drop in efficiency and potentially corrosive damage to plastic and rubber parts. Puri said these concerns are overstated and often the result of lobbying.
While Puri did not say the government plans to increase ethanol blending beyond E20 at petrol pumps, he noted that pure ethanol (E100) is now available at 400 petrol stations across the country (out of around 88,000). However, most modern petrol-tuned vehicles cannot run on blends higher than E20 without significant modifications to become 'flex-fuel' vehicles, as in Brazil, where cars can operate on a wide range of blends. The Petroleum Ministry is subtly promoting the idea of India's energy independence through biofuels, and as more E20-capable cars enter the fleet and older vehicles are scrapped, ethanol blending issues will gradually dissipate.
A senior auto industry executive told me the ideal scenario for India would be a 'baseline' of E20 petrol, with consumers free to choose higher or lower blends.
'If there is some differential pricing to account for the lower calorific value of ethanol, this will help in adoption. In heavy urban traffic, fuel economy losses will be marginal, and with strong or plug-in hybrid flex-fuel vehicles, losses would dissipate completely.'
Beyond biofuels—CBG, CNG
But biofuels go far beyond ethanol. The government's big push now is for Compressed Biogas (CBG), which will be blended into Compressed Natural Gas (CNG). Unlike ethanol, CBG and CNG are chemically identical. The target is for CBG to make up 4 percent of CNG by 2030.
'India has a huge amount of biomass, and it makes sense to use it for energy production. India's energy needs are increasing dramatically year-on-year, and we should be using this to make energy,' Vibha Dhawan, Director-General of The Energy and Resources Institute (TERI), told me.
In fact, according to a presentation by Maruti Suzuki, CBG—if properly accounted for—actually removes carbon from the atmosphere, since rotting biomass would otherwise release methane, a deadlier greenhouse gas than carbon dioxide. Capturing and burning it as vehicle fuel is a win-win, although Dhawan acknowledged there are still scalability issues and questions about how to handle the by-products. Maruti Suzuki is working with the National Dairy Development Board (NDDB) to find solutions, and CBG is likely to make headlines in the coming months.
The biofuels story doesn't end there. Puri also revealed that the IndianOil refinery in Panipat can now process used cooking oil to produce Sustainable Aviation Fuel (SAF).
'Going forward, more and more planes will run on a blend of SAF and conventional aviation fuel. This is a far more ecological use of used cooking oil,' Puri said.
Kushan Mitra is an automotive journalist based in New Delhi. He tweets @kushanmitra. Views are personal.
(Edited by Prashant)
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

'India's freedom of speech regulated by Israel?': Congress questions after envoy Reuven Azar ‘targets' Priyanka Gandhi
'India's freedom of speech regulated by Israel?': Congress questions after envoy Reuven Azar ‘targets' Priyanka Gandhi

Mint

time8 minutes ago

  • Mint

'India's freedom of speech regulated by Israel?': Congress questions after envoy Reuven Azar ‘targets' Priyanka Gandhi

Congress leader Pawan Khera on Wednesday, launched a scathing attack on Israel Ambassador Reuven Azar after his criticism of Priyanka Gandhi Vadra, who had accused Tel Aviv of 'genocide' and criticising the Indian government for its 'silence' on the matter. In a strongly worded post on social media platform X, Khera slammed Reuven Azar, stating that him 'targeting' a sitting Member of the Indian Parliament is 'both unprecedented and intolerable.' The Congress leader further tagged S Jaishankar, questioning if 'freedom of speech in India' had now 'begun to be regulated from Israel." Following Priyanka Gandhi's post on X, Israeli Ambassador to India Reuven Azar accused the Congress leader of spreading 'deceit' and presented Israel's version of the conflict's toll. 'What is shameful is your deceit. Israel killed 25,000 Hamas terrorists. The terrible cost in human lives derives from Hamas's heinous tactics of hiding behind civilians, their shooting of people trying to evacuate or receive assistance and their rocket fire,' Azar said in his post. The Israeli diplomat's post comes after Priyanka Gandhi alleged that Israel 'murdered over 60,000 people, 18,430 of whom were children', starved hundreds to death, and was threatening to starve millions more. 'Enabling these crimes by silence and inaction is a crime in itself. It is shameful that the Indian Government stands silent as Israel unleashes this devastation on the people of Palestine,' she wroteon X, on Tuesday. Apart from Pawan Khera, Congress's Gaurav Gogoi also hit out at the Israeli ambassador, stating that the 'Parliament cannot remain a passive spectator.' "The disparaging comments made by a foreign Ambassador against a Member of Parliament of India is a serious breach of privilege. Even if the Union Government is silent, the Parliament cannot remain a passive spectator..." he said on X. Veteran Congress leader and former Union Minister Anand Sharma also strongly condemned the remarks of the Israeli Ambassador to India, "denying" the humanitarian crisis of Gaza, saying that the language used by the Israeli representative and "undiplomatic, distasteful and unacceptable," while the brutality, destruction of schools, hospitals and mass starvation is taking place. As Israel continues its bombardment, the IDF said it has approved the "framework" for a new offensive in the Gaza Strip, days after the security cabinet called for the seizure of Gaza City, reported AFP. On Tuesday, Gaza's Health Ministry reported that five more Palestinians have died from hunger, bringing the total number of starvation-related deaths to 227, including 103 children.

Nifty Pharma index rises 1.9%:  Alkem, Zydus among key gainers: Should you buy or sell pharma stocks?
Nifty Pharma index rises 1.9%:  Alkem, Zydus among key gainers: Should you buy or sell pharma stocks?

Mint

time8 minutes ago

  • Mint

Nifty Pharma index rises 1.9%: Alkem, Zydus among key gainers: Should you buy or sell pharma stocks?

Stock Market Today: The Nifty Pharma index gained 1.9% during the intraday trades on Wednesday. Alkem and Zydus stood among key gainers that led the rally The Nifty Pharma Index gained almost 2% during the intraday trade on Wednesday amid a relief rally in the Indian stock market. The Nifty Pharma Index opened at 21,803.45 levels, higher than the previous day's closing price of 21,753.50. It continued to gain further to an intraday high of 22,171.05, which meant gains of almost 2% over the previous day's close. Alkem Laboratories, Zydus Lifesciences, Laurus Labs, and Abbott India were among the key gainers that led to the rise in the Nifty Pharma pack. The US market remains critical for many Indian pharma companies. Sun Pharmaceuticals, Lupin , Dr. Reddy's, Aurobindo, Cipla, and many more derive a significant part of revenues from the US markets. Thus the danger of a 50% tax on pharmaceuticals looms, and this clearly poses a risk to the profitability of Indian pharmaceutical businesses, which rely on the US market for 30-50% of their sales. Most of these US revenues, however, come from the generic drug segment. Silver lining The silver lining remains as India remains cost-competitive compared to both the US and global peers, which should help mitigate some risks, said Ajit Banerjee, president and chief investment officer at Shriram Life Insurance. The domestic Indian pharma market (50% of the Indian pharmaceutical market) will remain unaffected by tariffs. Within the US, the impact on the generic formulations market is still uncertain, though Indian players already operate on thin margins. Tariffs could increase the drug shortages by eliminating competition in a market where pricing pressures are already intense, which could be a positive for Indian companies over the mid- to long-term, highlighted Banerjee While the recent executive order by the US Administration excludes the pharmaceutical sector from immediate tariff imposition. Any tariff action will depend on the outcome of the ongoing investigation under Section 232 of the Trade Expansion Act of 1962. Even if the India pharma tariff question is answered, Kotak Institutional expect the uncertainty to persist around whether the anticipated pharma tariffs (post the Section 232 investigation) would add to the country-specific one, definition of pharma/pharma products and then eventually how much of the tariffs are passed on and rolled back Bannerjee believes the US can either bring manufacturing back home or reduce drug prices, but not both simultaneously. Even before tariffs are finalized, the uncertainty can lead to delays in order commitments and impact sector sentiment and stock price thereby. The sector currently trades at a 1Y forward P/E of 29.7 times, above its 10-year average of 26.7x. We see tariff-induced volatility as a chance for investors to accumulate quality pharma stocks on dips, said Banerjee. Nifty Pharma has witnessed two weeks of selling pressure, especially after the recent U.S. tariff developments, as per analysts. The Pharma Index was trading near a support level on the daily time frame, where a pause in the decline was expected in the coming days, potentially leading the index towards 21,998. The outlook remains negative as long as the index fails to sustain above 22,380. On the downside, a break below 21,240 could push the index further towards the 20,380–20,140 zone, as per Kunal Kamble, Sr. Technical Research Analyst at Bonanza * Disclaimer: The views and recommendations above are those of individual analysts or brokerage companies, not Mint. We advise investors to check with certified experts before making any investment decisions.

Bulls ride high on India stocks, expecting success of US-Russia talks on Ukraine
Bulls ride high on India stocks, expecting success of US-Russia talks on Ukraine

Mint

time8 minutes ago

  • Mint

Bulls ride high on India stocks, expecting success of US-Russia talks on Ukraine

Bulls appeared to be taking charge of the stock markets on Wednesday, ahead of the Trump-Putin talks, where a breakthrough or an impasse could significantly impact Indian equities. The two leaders are slated to meet in Alaska on Friday in a bid to end the over-three year Ukraine war. A day after foreign portfolio investors trimmed their index future longs to 7.95%, only 20 basis points shy of the record low of 7.75% on 22 March 2023, in light of the US Fed rate tightening cycle, bulls sold huge quantities of put options between the 24,500 and 24,600 levels, expecting a rally in the markets ahead of the talks. The contracts expire tomorrow. The Nifty 50 traded 0.6% higher at 24,634 at 1 pm. Amid likely domestic institutional investor buying in the cash market, bulls sold a massive number of puts at 24,600 – the open position at this strike rose by a whopping 227,758 contracts to a total 284,785 contracts. At 24,550, the open or outstanding positions jumped 148,077 contracts to 193,635 contracts and at 24,500 by 152,528 contracts to 260,034 contracts. The jump in open positions at these levels indicates that bulls expect the markets to close at or above 24,600, which will enable them to pocket the premium paid by the put buyers, who expect the markets to correct. "The correction premise (of put buyers) is based on the talks stalling and a continuation of the war, which could impact countries like India that buy Russian oil and have been slapped with a proposed punitive tariff of 25% from 27 August," explained SK Joshi, a consultant with Khambatta Securities. Other analysts cautioned that it was too early to take such calls because the Indian markets would react to the outcome of the talks only on Monday, with Friday a holiday for Independence Day. "The market is likely to consolidate in a 24,400-24,700 range ahead of the Russia-US talks in Alaska," said Sahaj Agrawal, head of derivatives research at Kotak Securities. "The reaction to the outcome will be on Monday." Options data and sentiment for now also suggest a sideways movement, with no major horizon shift on the cards, he added. The put-call ratio of the weekly options expiring on Thursday stood at 0.99 intraday, which means that for every 100 calls sold, traders had sold 99 puts. On Tuesday, the ratio stood at 0.65, or only 65 puts sold for 100 calls sold. Time correction The benchmark Nifty 50 has been in a time correction for 11 months now, which is longer than the nine-month time correction that followed the outbreak of the covid pandemic in 2020. Time correction implies an extended period of stagnant to marginally lower price movement. The Nifty has fallen 6.25% from a record high of 26,277.35 on 27 September last year to Wednesday's intraday level of 24,634. While the Nasdaq, the UK's FTSE and Japan's Nikkei trade at record highs, Indian stock indices haven't been able to reclaim their previous high even 11 months later. In the last major down-cycle, the Nifty fell 40% from a high of 12,430 on 20 January 2020 to 7,511.10 on 24 March that year when the pandemic surfaced. However, it reclaimed the high in nine months, closing at 12,632 by 9 November. The current time correction is due to tepid earnings growth and more lately because of Trump's crushing tariffs on India, which Moody's expects could trim its current fiscal growth estimate by 30 bps to 6%. "We have been in a time correction for nearly 11 months now and will have to see how the geopolitical events play out to reckon whether we will break through the 26,277.35 record high of last September or test the multi-month low of 21,743.65 of this April," Kotak Securities' Agrawal added.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store